Still A Binary Phase III Bet on Evenamide

Rating: Speculative Buy / Clinical-event driven

Style: Small-cap biotech with one dominant value driver

Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else?

Executive view

Newron is now essentially an evenamide company. The investment case is built overwhelmingly around one lead asset: a first-in-class glutamate modulator being developed as an add-on therapy for treatment-resistant schizophrenia (TRS) and for patients with poorly responding schizophrenia. The attraction is obvious: schizophrenia remains a high-unmet-need market, and Newron’s core pitch is that evenamide could become the first approved add-on therapy for TRS rather than just another antipsychotic with a similar mechanism.

The stock is interesting now because the company has moved beyond promising Phase II data and is fully into the pivotal Phase III ENIGMA-TRS program. Newron said in March 2026 that 2026 is expected to be a key year for clinical progress, and in December 2025 it stated that topline results from ENIGMA-TRS 2 are expected in Q4 2026. This is the type of setup where value can move sharply in either direction on one catalyst.

At the same time, this is still a biotech with limited diversification, no broad commercial revenue engine, and a valuation that depends heavily on clinical success probabilities. Newron ended 2025 with €28.9 million of cash, cash equivalents and other current financial assets, but it has also had to actively strengthen funding, including a February 2026 financing package of up to €38 million and a March 2026 agreement to push EIB debt maturities out to June 28, 2028. That improves runway, but it also reminds you this is not yet a self-funding business.

Why now ? Newron has become a late-stage catalyst story

The reason Newron matters now is that the story has become much more concrete. In 2025, the company announced regulatory approval for its pivotal Phase III ENIGMA-TRS program, comprising ENIGMA-TRS 1 and ENIGMA-TRS 2. ENIGMA-TRS 1 began in August 2025, and ENIGMA-TRS 2 began in the U.S. in December 2025 after FDA and IRB approvals.

The second reason is financing. In February 2026, Newron said it had secured up to €38 million from a group of existing and new shareholders, with the proceeds expected to fund the global Phase III evenamide program and extend cash runway beyond the pivotal 12-week results. A month later, the company also said it had agreed with the European Investment Bank to extend all outstanding tranche maturities under its 2018 finance contract to June 28, 2028. That combination materially reduces near-term financing pressure going into the key trial window.

The third reason is IP and partnering progress. Newron said in March 2026 that the European Patent Office granted an additional composition-of-matter patent through 2044 for evenamide, extending the exclusivity runway, and it noted that partner EA Pharma (Eisai Group) had initiated a Phase III trial in Japan and other designated Asian territories. That does not eliminate risk, but it does strengthen the strategic profile of the asset.

What Newron does

Newron is a CNS-focused biopharmaceutical company, but in practical valuation terms it is now mostly a one-lead-asset business. The company still has Xadago royalties and milestones from licensing arrangements, but evenamide is clearly the central value driver. Its own corporate materials describe evenamide as the lead compound and frame it as a potential first add-on therapy for TRS and poorly responding schizophrenia.

That concentration cuts both ways. On the positive side, it means the story is easy to understand. On the negative side, it means there is little diversification if evenamide disappoints.

How they win — differentiation in an area of real unmet need

Newron only wins if evenamide proves meaningfully differentiated. The company’s scientific thesis is that evenamide has a novel mechanism, selectively inhibiting voltage-gated sodium channels in hyperactive neurons and normalizing glutamatergic dysfunction, which it argues is relevant in patients who do not respond well to existing antipsychotics. In other words, this is supposed to be mechanistically different from simply tweaking the current dopamine-centric toolkit.

That matters because the clinical need is real. Newron explicitly notes that TRS patients often have little or no meaningful benefit from currently available antipsychotics. If evenamide can show efficacy with good tolerability as an add-on therapy, that would be commercially and clinically relevant. The company also continues to cite earlier studies 014/015 and 008A as showing clinically meaningful improvements with a favorable safety profile.

The other way Newron can win is through partnering. It has already licensed rights in Japan and other designated Asian territories to EA Pharma, and management has repeatedly pointed to partnering in non-core markets as part of the strategy. That matters because a small biotech rarely maximizes value by trying to build a global commercial infrastructure on its own.

How they make money

Today, Newron does not have a broad operating model in the normal sense. Its 2025 financial results still reflect a small biotech profile rather than a commercial-stage CNS company. The future value creation path is likely to come from a mix of milestones, partnerships, royalties, and potentially direct commercialization in selected markets, if evenamide succeeds.

That means investors should not think about Newron the way they would think about a steadily compounding pharmaceutical company. This is a clinical-value realization story, where major share-price moves are mostly driven by trial outcomes, deal terms, and financing structure.

By the numbers

The most important current numbers are the financing and market setup. In its March 2026 FY2025 results, Newron reported €28.876 million in cash, cash equivalents and other current financial assets, versus €9.826 million a year earlier. It also reported cash generated from operating activities of €32.349 million, helped by milestone-related flows, and total assets of €40.055 million.

On the equity side, Newron’s shares were recently trading around CHF 13.60 on SIX. Public market sources put the market cap around CHF 283 million or roughly $360 million, depending on currency conversion and venue.

Those numbers highlight the setup well: Newron is no longer a microcap orphan, but it is still small enough that a strong Phase III readout could move valuation very materially.

Key drivers — what can move the stock higher

• The single biggest driver is Phase III execution and topline efficacy data. ENIGMA-TRS 2 is a global, randomized, double-blind, placebo-controlled 12-week Phase III trial expected to enroll at least 400 patients, with topline results expected in Q4 2026. ENIGMA-TRS 1 is also underway as a longer one-year study in at least 600 patients. If the 12-week results are positive, the stock likely rerates sharply. If they are weak or ambiguous, the downside is likely severe.
• The second driver is partnering and regional value realization. The Japan Phase III start by EA Pharma is a useful proof point because it shows that external parties are willing to fund development in licensed territories. Additional partnerships outside the U.S. could further reduce financing needs and validate the asset.
• The third driver is patent life and commercial durability. The new European patent through 2044 matters because a CNS asset with strong clinical data but weak exclusivity is worth much less than one with a long runway.

Risks — what could go wrong

• The biggest risk is obvious: clinical failure. This is a one-asset story. If evenamide misses in Phase III or produces data that regulators or partners view as commercially insufficient, the equity value would likely compress dramatically.
• The second risk is financing and dilution. Newron has improved its runway, but biotech development remains capital intensive. The February 2026 financing and the EIB maturity extension helped, but they do not remove future capital needs if timelines extend or if commercialization is pursued more aggressively.
• The third risk is execution risk in a complex global Phase III program. ENIGMA-TRS 1 and 2 are multinational studies with strict TRS eligibility requirements and an independent eligibility assessment committee. That supports trial quality, but it also adds operational complexity.
• The fourth risk is single-asset concentration. Even with Xadago-related economics and legacy assets, Newron’s value is highly concentrated in evenamide. That creates binary behavior in the stock.

Bottom line

Bull case: Newron has one of the more interesting late-stage European biotech setups in CNS because evenamide is differentiated, the unmet need in TRS is real, the patent runway has improved, the Japan partner is active, and the company has now funded itself past the key Phase III readout window. If Q4 2026 data are positive, the current market cap could prove modest.

Bear case: this is still a binary biotech. There is very little room to hide if evenamide disappoints, and the market is already capitalizing a substantial probability of success given the move from last year’s lows.

Investment conclusion: I would frame Newron as a Speculative Buy. It is not a stock to own for stability; it is a stock to own only if you are willing to underwrite a very large clinical event. But among that kind of setup, Newron now looks better funded, more advanced, and more strategically credible than it did a year ago.

Fair value estimate

My current fair value estimate for Newron is CHF 18 per share.

With the stock around CHF 13.60, that implies roughly 32% upside.

Why CHF 18? Because that level gives Newron credit for:

• a better-funded path through the Q4 2026 topline data event,
• a stronger IP position through 2044,
• partner validation in Japan,
• and a modest increase in the market-implied probability of success for evenamide — but not full Phase III success or a best-case commercial outcome.

For context, an external ValuationLab flash update published on Newron’s website in April 2025 showed a risk-adjusted NPV of CHF 23.0 per share, though that was before the 2026 financing and should be treated as one third-party model rather than a fact.